Prognostic implications of expression of the cell cycle inhibitor protein p27(Kip1)

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 29-41

  Cariou, Sandrine ^a   Catzavelos, Charles ^a   Slingerland, Joyce M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cdk inhibitor; Cell cycle; Cyclin dependent kinase (cdk); p27; Prognostic factor

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; FLUOROURACIL; GROWTH INHIBITOR; INHIBITOR PROTEIN; METHOTREXATE; PACLITAXEL; PROTEASOME; PROTEIN P27;

ADHESION; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; COLON CANCER; ESOPHAGUS CANCER; GENE MUTATION; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; STOMACH CANCER; THERAPY; TUMOR GROWTH;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032444464     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006154900130     Document Type: Review

References (95)

1. Solomon MJ: Activation of the various cyclin/cdc2 proteins. Current Opinions in Cell Biology 5:180-186, 1993
2. Morgan DO: Principles of Cdk regulation. Nature 374:131-134, 1995
3. Sherr CJ: G1 phase progression: cycling on cue. Cell 79:551-555, 1994
4. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
5. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl 18:69-73, 1994
6. Murray AW: Creative blocks: Cell cycle checkpoints and feedback controls. Nature 359:599-604, 1992
7. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992
8. El-Deiry WS, Tokino T, Velculescu VE, Levy D, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor supression. Cell 75:817-825, 1993
9. Gu Y, Turck CW, Morgan DO: Inhibition of Cdk2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710, 1993
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependant kinases. Cell 75:805-816, 1993
11. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994
12. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994
13. Polyak C, Lee M-H, Erdjument-Romage H, Koff A, Roberts J, Tempst P, Massague J: Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
14. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994
15. Lee M-H, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with a unique domain structure and tissue distribution. Genes Dev 9:639-649, 1995
16. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIPl Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995
17. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olsen EN, Harper JW, Elledge SJ: p53-independent expression of p21CIP1 in muscle and other terminally differentiating cells. Science 267:1024-1028, 1995
18. Skapek SX, Rhee J, Spicer DB, Lassar AB: Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024, 1995
19. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon G, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1022, 1995
20. Flores-Rosas H, Kelman Z, Dean FB, Pan Z, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J: Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc Natl Acad Sci USA 91:8655-8659, 1994
21. Li R, Waga S, Hannon G, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534-537, 1994
22. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994
23. Dulic V, Kaufman WK, Wilson SJ, Tosty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994
24. Petrocelli T, Poon R, Drucker D, Slingerland J, Rosen C: UVB irradiation induces p21Cipl/WAF1 and mediates G1 and S phase checkpoints. Oncogene 12:1387-1396, 1996
25. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J: Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-539, 1993
26. Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14:3683-3694, 1994
27. Firpo EJ, Koff A, Solomon MJ, Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 14:4889-4901, 1994
28. Bernhard EJ, Maity A, Muschel RJ, McKenna WG: Effects of ionizing radiation on cell cycle progression. A review. Radiat Environ Biophys 34:79-83, 1995
29. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573, 1994
30. Kip1. Oncogene 13:2447-2547, 1996
31. Hall M, Bates S, Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588, 1995
32. Poon R, Toyoshima H, Hunter T: Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet light. Mol Biol Cell 6:1197-1213, 1995
33. Harper JW, Elledge S, Keyomarsi K, Dynlacht B, Tsai L-H, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995
34. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994
35. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/Cdk4. Nature 366:704-707, 1993
36. Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu Y, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994
37. Chan K-MF, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16-INK4. Mol Cell Biol 15:2682-2688, 1995
38. Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681, 1995
39. Sandhu C, Garbe J, Daksis J, Pan C-H, Bhattacharya N, Yaswen P, Koh I, Slingerland J, Stampfer MR: TGF-β stabilizes p15INK4B protein, increases p15INK4B/cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. Mol Cell Biol 17:2458-2467, 1997
40. Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503-511, 1995
41. Cairns P, Mao L, Merlo A, Lee D, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994
42. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics 11:210-212, 1995
43. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and cdk inhibitors come of age. Cell 79:573-582, 1994
44. Bates S, Peters G: Cyclin D1 as a cellular proto-oncogene. Semin Cancer Biol 6:73-82, 1995
45. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergmann W, Frants R, Goldhar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics 8:22-26, 1994
46. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor in multiple human cancers. Nature 368: 753-756, 1994
47. Hengst L, Dulic V, Slingerland J, Lees E, Reed SI: A cell cycle regulated inhibitor of cyclin dependent kinases. Proc Natl Acad Sci USA 91:5291-5294, 1994
48. Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487-496, 1994
49. Kip1. Genes Dev 11:2335-2346, 1997
50. Durand B, Gao FB, Raff M: Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 16:306-317, 1997
51. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87:1069-1078, 1996
52. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721-732, 1996
53. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996
54. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Polyak K, Firpo E, Tsai L, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 85:733-744, 1996
55. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995
56. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996
57. Pagano M, Beer-Romero P, Glass S, Tam S, Theodoras A, Rolfe M, Draetta G: Targeting ubiquitin-mediated degradation for proliferation inhibitors. Seventh Pezcoller Symposium, Cancer Genes: Functional Aspects, 1995
58. Kip1. Mol Cell Biol 17:3850-3857, 1997
59. Takuwa N, Takuwa Y: Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 17:5348-5358, 1997
60. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637, 1997
61. Alessandrini A, Chiaur DS, Erikson R, Pagano M: Regulation of the cyclin-depedent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345, 1997
62. Kip1. EMBO J 16:5334-5344, 1997
63. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11:1464-1478, 1997
64. Kip1 is abrogated by c-Myc. EMBO J 15:6595-6604, 1996
65. Assoian RK: Anchorage-dependent cell cycle progression. J Cell Biol 136:1-3, 1997
66. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133:391-403, 1996
67. Fang FG, Watanabe N, Hunter T, Ruoslahti E: Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science 271:499-502, 1996
68. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingedand J, Dedhar S: Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 272: 13937-13944, 1997
69. St Croix B, Florenes V, Rak A, Flanagan JW, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nature Medicine 2:1204-1210, 1996
70. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995
71. Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res 55:1211-1214, 1995
72. Kip1 in human malignancies. Cancer Res 55:2266-2269, 1995
73. Ferrando A, Balbin M, Pendas AM, Vizoso F, Velasco G, Lopez-Otin C: Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Human Genetics 97:91-94, 1996
74. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3:227-230, 1997
75. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3:222-225, 1997
76. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinomas. Cancer Res 57:1259-1263, 1997
77. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385, 1997
78. Kip1 in human breast cancers. Clin Cancer Res 3:1879-1887, 1997
79. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased protea-some-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3:231-234, 1997
80. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548, 1998
81. Yang RM, Naitoh J, Philipson J, Wang H, deKernion JB, Loda M, Reiter RE: Low levels of p27 protein expression predict poor disease-free survival in patients with pathological T2a-T3b adenocarcinoma of the prostate. J Urol 159:941-945, 1998
82. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 3:593, 1997
83. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Research 58:1730-1735, 1998
84. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic rote of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385, 1997
85. Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Submitted, 1998
86. Kip1 in malignant melanoma: Inverse correlation with disease-free survival. Am J Pathol 153:305-312, 1998
87. Allessandrini A, Chiaur DS, Pagano M: Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345, 1997
88. Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997
89. KIP1 in epithelial dysplasia and carcinoma of the oral cavity. Submitted, Am J Pathol, 1998
90. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
91. Masood S: Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Surg Oncol Clin N Am 4:601-632, 1995
92. Jordan VC: "Studies on the estrogen receptor in breast cancer" - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285, 1995
93. Muss HB, Thor AD, Berry DA, Kute T, Liu E, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1268, 1994
94. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
95. Levin MN, Pritchard KI, Bramwell V, et al: A randomized trial of cyclophosphamide, Epirubicin, fluorouracil chemotherapy compared with cyclophos-phamide, methotrexate, fluorouracil in post menopausal women with node-negative breast cancer. J Clin Oncol, in press